PMID- 36029009 OWN - NLM STAT- MEDLINE DCOM- 20220830 LR - 20230701 IS - 2040-2058 (Electronic) IS - 1359-6535 (Print) IS - 1359-6535 (Linking) VI - 27 IP - 3 DP - 2022 Jun TI - Outcomes of etravirine-based antiretroviral treatment in treatment-experienced children and adolescents living with HIV in Europe and Thailand. PG - 13596535221092182 LID - 10.1177/13596535221092182 [doi] AB - BACKGROUND: Etravirine (ETR) is approved as a component of second or third-line antiretroviral treatment (ART) for children living with HIV. We assessed the outcomes of ETR-based ART in children in routine care in Europe and Thailand. METHODS: Data on children aged <18 years at ETR start were pooled from 17 observational cohorts. Characteristics at ETR start, immunological and virological outcomes at 12 months, discontinuations, adverse events (AEs) and serious adverse events (SAEs) were described. Follow-up was censored at ETR discontinuation, death or last visit. RESULTS: 177 children ever received ETR. At ETR start, median [IQR] age was 15 [12,16] years, CD4 count 480 [287, 713] cells/mm(3), 70% had exposure to >/=3 ART classes and 20% had viral load (VL) <50 copies/mL. 95% received ETR in combination with >/=1 potent drug class, mostly protease inhibitor-based regimens. Median time on ETR was 24 [7, 48] months. Amongst those on ETR at 12 months (n=141), 69% had VL<50 copies/mL. Median CD4 increase since ETR start (n=83) was 147 [16, 267] cells/mm(3). Overall, 81 (46%) discontinued ETR by last follow-up. Median time to discontinuation was 23 [8, 47] months. Common reasons for discontinuation were treatment simplification (19%), treatment failure (16%) and toxicity (12%). Eight children (5%) had AEs causally associated with ETR, all dermatological/hypersensitivity reactions. Two were SAEs, both Stevens-Johnson Syndrome in children on regimens containing ETR and darunavir and were causally related to either drugs; both resolved following ART discontinuation. CONCLUSION: Children receiving ETR were predominantly highly treatment-experienced, over two-thirds were virally suppressed at 12 months. FAU - European Pregnancy And Paediatric Infections Cohort Collaboration Eppicc AU - European Pregnancy And Paediatric Infections Cohort Collaboration Eppicc FAU - Lyons, Alex AU - Lyons A AD - MRC Clinical Trials Unit at UCL, 4919University College London, London, UK. FAU - Thompson, Lindsay AU - Thompson L AD - MRC Clinical Trials Unit at UCL, 4919University College London, London, UK. FAU - Chappell, Elizabeth AU - Chappell E AD - MRC Clinical Trials Unit at UCL, 4919University College London, London, UK. FAU - Ene, Luminita AU - Ene L AD - Clinical Department of Infectious Diseases (HIV Department), Dr. Victor Babes Hospital for Infectious and Tropical Diseases, Bucharest, Romania. FAU - Galli, Luisa AU - Galli L AD - Infectious Disease Unit, Meyer Children's Hospital, Department of Health Sciences, University of Florence, Florence, Italy. FAU - Goetghebuer, Tessa AU - Goetghebuer T AD - Hopital St Pierre, Brussels, Belgium. FAU - Jourdain, Gonzague AU - Jourdain G AD - Institut de recherche pour le developpement (IRD)-PHPT, Marseille, France. AD - Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand. FAU - Noguera-Julian, Antoni AU - Noguera-Julian A AD - Infectious Diseases and Systemic Inflammatory Response in Pediatrics, Infectious Diseases Unit, Department of Pediatrics, Sant Joan de Deu Hospital Research Foundation, Barcelona, Spain. FAU - Kahlert, Christian R AU - Kahlert CR AD - Infectious Diseases and Hospital Epidemiology, Children's Hospital of Eastern Switzerland and Cantonal Hospital, St Gallen, Switzerland. FAU - Konigs, Christoph AU - Konigs C AD - Department for Children and Adolescents, Division for Stem Cell Transplantation and Immunology, University Hospital Frankfurt/Main, Frankfurt, Germany. FAU - Kosalaraksa, Pope AU - Kosalaraksa P AD - Department of Pediatrics, Khon Kaen University, Khon Kaen, Thailand. FAU - Lumbiganon, Pagakrong AU - Lumbiganon P AD - Department of Pediatrics, Khon Kaen University, Khon Kaen, Thailand. FAU - Marczynska, Magdalena AU - Marczynska M AD - Hospital of Infectious Diseases, 37803Medical University of Warsaw, Warsaw, Poland. FAU - Marques, Laura AU - Marques L AD - Centro Hospitalar e Universitario do Porto, Porto, Portugal. FAU - Navarro, Marissa AU - Navarro M AD - Hospital General Universitario "Gregorio Maranon", Madrid, Spain. AD - 16734Universidad Complutense, Madrid, Spain. AD - 559924Instituto de Investigacion Sanitaria Gregorio Maranon (IISGM), Madrid, Spain. AD - Red de Investigacion Translacional en Infectologia Pediatrica, RITIP, Madrid, Spain. FAU - Naver, Lars AU - Naver L AD - Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden. FAU - Okhonskaia, Liubov AU - Okhonskaia L AD - Federal Budgetary Institution "Republican Clinical Infectious Hospital" of the Ministry of Health of the Russian Federation, Saint-Petersburg, Russian Federation. FAU - Prata, Filipa AU - Prata F AD - Hospital de Santa Maria/CHULN, Lisbon, Portugal. FAU - Puthanakit, Thanyawee AU - Puthanakit T AD - Department of Pediatrics, Faculty of Medicine, 26683Chulalongkorn University and HIVNAT, Thai Red Cross AIDS Research Center, Bangkok, Thailand. FAU - Ramos, Jose T AU - Ramos JT AD - Departamento de Salud Publica y Materno-infantil, Universidad Complutense, Hospital Clinico San Carlos, Instituto de Investigacion Sanitaria del Hospital Clinico San Carlos (IdISSC), Madrid, Spain. FAU - Samarina, Anna AU - Samarina A AD - The City HIV Centre, St Petersburg City AIDS Center, St Petersburg, Russian Federation. FAU - Thorne, Claire AU - Thorne C AD - University College London Great Ormond Street Institute of Child Health, London, UK. FAU - Voronin, Evgeny AU - Voronin E AD - Federal Budgetary Institution "Republican Clinical Infectious Hospital" of the Ministry of Health of the Russian Federation, Saint-Petersburg, Russian Federation. FAU - Turkova, Anna AU - Turkova A AD - MRC Clinical Trials Unit at UCL, 4919University College London, London, UK. AD - 4956Great Ormond Street Hospital, London, UK. FAU - Giaquinto, Carlo AU - Giaquinto C AD - 561043Paediatric European Network for the Treatment of AIDS (Penta), Padova, Italy. FAU - Judd, Ali AU - Judd A AD - MRC Clinical Trials Unit at UCL, 4919University College London, London, UK. FAU - Collins, Intira J AU - Collins IJ AUID- ORCID: 0000-0003-2132-6037 AD - MRC Clinical Trials Unit at UCL, 4919University College London, London, UK. LA - eng GR - MC_UU_00004/03/MRC_/Medical Research Council/United Kingdom GR - MC_UU_12023/26/MRC_/Medical Research Council/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - Antivir Ther JT - Antiviral therapy JID - 9815705 RN - 0 (Anti-HIV Agents) RN - 0 (Anti-Retroviral Agents) RN - 0 (Nitriles) RN - 0 (Pyridazines) RN - 0 (Pyrimidines) RN - 0C50HW4FO1 (etravirine) SB - IM MH - Adolescent MH - *Anti-HIV Agents MH - Anti-Retroviral Agents MH - CD4 Lymphocyte Count MH - Child MH - *HIV Infections MH - Humans MH - Nitriles MH - *Pyridazines MH - Pyrimidines MH - Thailand MH - Treatment Outcome MH - Viral Load PMC - PMC7614682 MID - EMS176878 COIS- Declaration of conflicting interests The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: AL report grant funding via Penta Foundation from Janssen-Cilag. IJC and AJ report grant funding via Penta Foundation from ViiV Healthcare, AbbVie, Janssen-Cilag and Gilead. EC reports grant funding via Penta Foundation from ViiV Healthcare. CT reports grant funding via Penta Foundation from ViiV Healthcare and Merck. EDAT- 2022/08/28 06:00 MHDA- 2022/08/31 06:00 PMCR- 2023/06/21 CRDT- 2022/08/27 02:12 PHST- 2022/08/27 02:12 [entrez] PHST- 2022/08/28 06:00 [pubmed] PHST- 2022/08/31 06:00 [medline] PHST- 2023/06/21 00:00 [pmc-release] AID - 10.1177/13596535221092182 [doi] PST - ppublish SO - Antivir Ther. 2022 Jun;27(3):13596535221092182. doi: 10.1177/13596535221092182.